Fifth Lane Capital’s Harmony Biosciences HRMY Stock Holding History

Fifth Lane Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,000	Closed	–	–	164
2023 Q4	$0	Buy	+100,000	New	+$2.79M	﹤0.01%	143

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fifth Lane Capital's HRMY Position: Q1 2024 in Review

Fifth Lane Capital sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 100,000 shares.

Fifth Lane Capital first reported a position in HRMY in Q4 2023 and held it in 1 quarter. The position peaked at $0 in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

Fifth Lane Capital reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
Fifth Lane Capital sold 100,000 Harmony Biosciences shares in Q1 2024.
Fifth Lane Capital first reported a position in Harmony Biosciences in Q4 2023 and held it in 1 quarter.
Fifth Lane Capital's Harmony Biosciences position peaked at $0 in Q4 2023.
208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Fifth Lane Capital's 13F filing for Q1 2024, filed 2 May 2024.